Multiple Plasmodium falciparum targets including phospholipid metabolism components and nucleic acids

This target profile represents a collection of essential molecular components within Plasmodium falciparum, specifically focusing on the enzymes of phospholipid metabolism and the parasite's nucleic acids. Phospholipid biosynthesis is a critical process for the parasite, as it must rapidly generate new membranes to support its growth and division within host red blood cells (PubMed: 10813151). Nucleic acids, including DNA and RNA, are fundamental for the replication and protein synthesis required for the parasite's complex life cycle (PubMed: 15563350). Drugs such as quinacrine (mepacrine) and pentamidine are known to interact with these targets; quinacrine intercalates into DNA and inhibits various enzymes, while pentamidine disrupts both nucleic acid synthesis and phospholipid metabolism (DrugBank: DB01103, DB00738). These interactions lead to the cessation of parasite growth and eventual cell death. However, because these pathways are also present in human cells, drugs targeting them can cause significant safety concerns, including hemolytic anemia in individuals with G6PD deficiency and potential neurotoxicity or cardiotoxicity (PubMed: 21673302). Monitoring efficacy typically involves measuring parasitemia levels or specific parasite proteins like histidine-rich protein 2 (PfHRP2). This multi-target approach is characteristic of several older antimalarial agents that exhibit broad-spectrum activity against the parasite's metabolic and genetic machinery.

Other names

Plasmodium falciparum phospholipid metabolism enzymesPlasmodium falciparum nucleic acidsMepacrine targetsPentamidine targets

Inhibition of nucleic acid synthesis and disruption of phospholipid metabolism